home > news > detailed info

Aragen launches royalty-free CHO GS cell line development platform under RapTr2022

Aragen Life Sciences

Delivers Titres up to 6g/L; Transfection to RCB in 18 weeks; RapTr2022 supports CHO GS and DG 44

October 27, 2022, California, USA: Aragen Life Sciences (Aragen), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), with eight facilities across India and the United States, today announced the launch of its newly optimized RapTr 2022 cell line development (CLD) platform. RapTr2022 offers a 33% reduction in CLD timelines and delivers increased titres up to 6g/l. This royalty-free platform now accelerates the process of cell line engineering -- from DNA transfection in the host cell lines to Research Cell Bank (RCB) -- all within 18 weeks. The RapTr CLD services include the proven CHO-DG44 and CHO-GS cell lines and proprietary vector combinations with an innovative clone selection process.

RapTr2022 has been developed at Aragen’s Morgan Hill campus in California, USA, by a team of expert scientists with more than two decades of experience in planning and designing engineered cell lines for therapeutic, diagnostic, and reagent generation applications. RapTr2022 provides cell bank clonality and consistency of product quality, and process performance throughout the lifecycle of the product, which are critical for a successful IND filing.

Speaking about RapTr2022, Manni Kantipudi, CEO, Aragen Life Sciences, said, “We are excited to launch RapTr 2022, which will help our customers increase their yield while significantly reducing the timeline for developing cell lines. The RapTr platform has proven capabilities to produce a range of biologics, including human, mouse, canine and feline IgGs, fusion proteins, enzymes, hormones, cytokines, mini bodies, and bispecific antibodies. With the launch of the RapTr2022 platform, our goal is to deliver clients’ products to clinics at speed while minimizing risk and maximizing efficiency.”

A key feature of RapTr2022 is the single-cell printer from CYTENA and Solentim imager. It is also supported by strong analytical capabilities that provide clients with a variety of methodologies for testing the purity, identity, potency, and stability of their monoclonal antibody (mAb) and recombinant protein products. These procedures are critical for the analysis and characterization of biologics as well as for guaranteeing the product’s safety, stability, and efficacy at all stages of development.
Print this page
Send to a friend
News and Press Releases

The Native Antigen Company Introduces New Range of Influenza Antigens

Oxford, UK, 16 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement